Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences.

被引：0
|
作者：
Ravi, Praful
Kelly, Emma
Whelpley, Bridget
Choudhury, Atish Dipankar
Sunkara, Rajitha
Pomerantz, Mark
Taplin, Mary-Ellen
Kilbridge, Kerry L.
Wei, Xiao X.
Morgans, Alicia K.
Bizzo, Renata Rocha de Almeida
Wolanski, Andrew
Jacene, Heather
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
108
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Formulation of clinical-scale 177Lu-PSMA-617: From laboratory to clinics
    Das, Tapas
    Guleria, Mohini
    Banerjee, Sharmila
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 836
  • [22] First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
    Thomas J. W. Klein Nulent
    Robert J. J. van Es
    Stefan M. Willems
    Arthur. J. A. T. Braat
    Lot A. Devriese
    Remco de Bree
    Bart de Keizer
    EJNMMI Research, 11
  • [23] First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
    Nulent, Thomas J. W. Klein
    van Es, Robert J. J.
    Willems, Stefan M.
    Braat, Arthur J. A. T.
    Devriese, Lot A.
    de Bree, Remco
    de Keizer, Bart
    EJNMMI RESEARCH, 2021, 11 (01)
  • [24] 177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better
    Sever, O. N.
    Elboga, U.
    Sahin, E.
    Cayirli, Y. B.
    Cinkir, H. Yesil
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (02): : 71 - 76
  • [25] Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Ho, Bao
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Hickey, Adam
    Eu, Peter
    Stockler, Martin
    Martin, Andrew J.
    Joshua, Anthony M.
    Nguyen, Andrew
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (02) : 221 - 226
  • [26] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [27] Initial Theranostics Experience Using 68Ga-PSMA-11 PET/CT and 177Lu-PSMA-617 in a Chilean Oncology Center
    Amaral, H.
    Fernandez, R.
    Kramer, V.
    Lavados, H.
    Hernandez, E.
    Morales, B.
    Pruzzo, R.
    Haeger, A.
    Ribbeck, J.
    Flores, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S205 - S205
  • [28] The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 343 - 343
  • [29] Patient outcomes after therapy with 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.
    Vaz, Nuno
    Ritzer, Jolivette
    Wolanski, Andrew
    Bhimaniya, Sudhir
    Choudhury, Atish Dipankar
    Hyun, Hyewon
    Kelly, Emma
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    Pomerantz, Mark
    Robertson, Matthew
    Sakellis, Christopher
    Shah, Hina
    Sunkara, Rajitha
    Taplin, Mary-Ellen
    Wei, Xiao X.
    Whelpley, Bridget
    Ravi, Praful
    Jacene, Heather
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 87 - 87
  • [30] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
12345